Table 1. Characteristics of eligible studies.
| Author | Year | Country | Number | Female | Age | Ever smoker | AC | Method | Sample | TNM (I/II/III/IV/other) | All EGFR mutations | Exon 19 deletion | L858R point mutation | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TP | FP | FN | TN | TP | FP | FN | TN | TP | FP | FN | TN | |||||||||||
| Lam D | 2015 | China | 74 | 36 | 65 ± 12 | 25 | 72 | PNA-LNA PCR | plasma | 0/0/4/70 | 34 | 1 | 9 | 30 | ||||||||
| Uchida J | 2015 | Japan | 288 | 119 | < 60 (66) | NR | 274 | Deep sequencing | plasma | 64/19/53/146/6 | 56 | 22 | 47 | 163 | 27 | 5 | 26 | 230 | 26 | 14 | 26 | 222 |
| Karachaliou N | 2015 | Spain | 97 | 68 | < 65 (45) | 26 | 93 | PNA clamp | serum | 0/0/4/93 | 47 | 0 | 9 | 41 | 29 | 0 | 12 | 56 | ||||
| Mok T | 2015 | China | 238 | NR | NR | NR | NR | AS-PCR | plasma | NR | 72 | 5 | 24 | 137 | 47 | 3 | 10 | 178 | 23 | 2 | 14 | 199 |
| Zhu G | 2015 | China | 86 | 30 | 55 (28-81) | 47 | 85 | ddPCR | plasma | 0/0/4/82 | 18 | 1 | 4 | 63 | 12 | 3 | 3 | 68 | ||||
| Douillard J | 2014 | France | 652 | NR | NR | NR | NR | ARMS | plasma | NR | 69 | 1 | 36 | 546 | 48 | 0 | 23 | 581 | 21 | 1 | 13 | 617 |
| Couraud S | 2014 | France | 59 | NR | NR | NR | NR | NGS | plasma | NR | 11 | 2 | 9 | 37 | 6 | 0 | 2 | 53 | ||||
| Weber B | 2014 | Denmark | 196 | NR | NR | NR | NR | AS-PCR | plasma | NR | 17 | 6 | 11 | 162 | ||||||||
| Li X (plasma) | 2014 | China | 121 | NR | NR | NR | NR | ARMS | plasma | NR | 27 | 3 | 29 | 62 | 17 | 2 | 16 | 86 | 11 | 2 | 12 | 97 |
| Li X (serum) | 2014 | China | 92 | NR | NR | NR | NR | ARMS | serum | NR | 19 | 2 | 29 | 42 | 12 | 1 | 15 | 64 | 7 | 1 | 14 | 70 |
| Wang S | 2014 | China | 134 | 65 | < 60 (90) | 62 | 108 | ARMS | plasma | 0/0/19/115 | 15 | 2 | 53 | 64 | ||||||||
| Jing C | 2013 | China | 120 | 51 | 62 (36-85) | NR | 70 | HRM | plasma | 38 (I/II)/ 82 (III/IV) | 29 | 2 | 16 | 73 | ||||||||
| Kim HR | 2013 | Korea | 40 | NR | NR | NR | NR | PNA | plasma | NR | 6 | 0 | 29 | 5 | ||||||||
| Kim ST | 2013 | Korea | 57 | 22 | 64 (28-84) | 32 | 40 | PNA-LNA PCR | serum | NR | 8 | 3 | 4 | 42 | ||||||||
| Zhang H | 2013 | China | 86 | 37 | 58 (21-80) | 44 | 65 | MEL | plasma | 0/0/16/70 | 15 | 0 | 7 | 64 | 8 | 0 | 6 | 72 | ||||
| Liu X | 2013 | China | 86 | 30 | 55 (28-81) | 47 | 85 | ARMS | plasma | 0/0/4/82 | 27 | 0 | 13 | 46 | ||||||||
| Hu C | 2012 | China | 47 | NR | NR | NR | 28 | HRM | serum | NR | 22 | 0 | 2 | 23 | ||||||||
| Zhao X | 2012 | China | 111 | 35 | < 60 (52) | 57 | 73 | ME-PCR | plasma | 22/10/33/46 | 16 | 3 | 29 | 63 | ||||||||
| Goto K | 2012 | Japan | 86 | NR | NR | NR | NR | ARMS | serum | NR | 22 | 0 | 29 | 35 | 11 | 0 | 18 | 57 | 10 | 0 | 12 | 64 |
| Xu F | 2012 | China | 34 | NR | NR | NR | NR | ARMS | serum | NR | 3 | 4 | 4 | 23 | 4 | 0 | 4 | 26 | ||||
| Huang Z | 2012 | China | 822 | 384 | ≤ 65 (519) | 340 | 641 | DHPLC | plasma | NR | 188 | 81 | 108 | 445 | ||||||||
| Jiang B | 2011 | China | 58 | 18 | 56 (43-80) | 36 | 42 | ME-sequencing | serum | NR | 14 | 0 | 4 | 40 | ||||||||
| Sriram K | 2011 | Australia | 64 | NR | NR | NR | NR | ME-PCR | serum | NR | 3 | 0 | 3 | 58 | ||||||||
| He C | 2009 | China | 18 | NR | NR | NR | NR | ME-PCR | plasma | NR | 8 | 1 | 0 | 9 | ||||||||
| Bai H | 2009 | China | 230 | 107 | 60.7 ± 4.5 | 103 | 171 | DHPLC | plasma | 0/0/80/150 | 63 | 16 | 14 | 137 | ||||||||
| Kuang Y | 2009 | USA | NR | NR | NR | NR | NR | ARMS | plasma | NR | 21 | 2 | 9 | 11 | ||||||||
| Kimura H | 2007 | Japan | 42 | 14 | 58 (40-81) | 28 | 31 | ARMS | serum | NR | 6 | 1 | 2 | 33 | ||||||||
PCR: polymerase chain reaction; PNA-LNA PCR: peptide nucleic acid-locked nucleic acid PCR; AS-PCR: allele-specific PCR; ARMS: scorpion amplification refractory mutation system; HRM: high resolution melting; ddPCR: droplet digital PCR; PNA: peptide nucleic acid-mediated PCR clamping; MEL: mutant-enriched liquidchip; ME-PCR: mutant-enriched PCR; DHPLC: denaturing high-performance liquid chromatography; ME sequencing: mutant-enriched sequencing; NGS: next-generation sequencing; NR: not reported; AC: adenocarcinoma; TNM: tumor node metastasis;
TP: true positive; FP: false positive; FN: false negative; TN: true negative.